Clinical Trial Update: Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating lanreotide versus placebo given before pancreatic surgery to reduce the risk of pancreatic fistula.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Somatuline (lanreotide)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Pancreatic Carcinoma, Pancreatic Neoplasm | Phase 3 | Status: RECRUITING